Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)

Pharmacosmos

Status: Completed

Conditions: Iron Deficiency Anaemia

Treatments: Drug: 10% Iron Isomaltoside 1000

Study type: Observational

Funder types: Industry

Identifiers

NCT02546154

Monofer-NIS-07

Details and patient eligibility

About

The objective is to monitor and quality assure the efficacy, including effects on quality of life, and safety of Monofer® in Chronic Kidney Disease and Inflammatory Bowel Disease patient populations when Monofer® is used according to the Monofer® label (Summary of Product Characteristics, SPC) in current clinical practice and where standard routines are being followed.

Full description

Intravenous (IV) iron is a well-tolerated and efficacious treatment of iron deficiency anaemia in conditions such as Chronic Kidney Disease (CKD) and Inflammatory Bowel Disease (IBD). Several studies in CKD and IBD patients have shown that IV iron is superior to oral iron, most likely explained by decreased uptake and poor compliance (due to gastrointestinal side-effects) when using oral iron.

The patented Iron Isomaltoside 1000 (Monofer®) has been developed to overcome the current limitations of IV iron drugs with regards to safety and convenience of use. The possibility to administer Monofer® at high single doses (up to 20 mg/kg) reduces the number of treatment visits needed for full iron correction, which is cost-effective, resource and time-sparing, and a reduced drug exposure frequency decreases the risk of side-effects such as infusion reactions.

The objective of the study is to monitor and quality assure the efficacy, including effects on quality of life, and safety of Monofer® in CKD and IBD patient populations when Monofer® is used according to the Monofer® label (Summary of Product Characteristics, SPC) in current clinical practice and where standard routines are being followed. The scientific rationale being to fulfill a need for systematic information/auditing on applied practice including both short and long-term experience with the use of IV iron in different hospital settings and in current clinical practice. The outcome will provide an evidence base for optimised treatment procedures in terms of safety and efficacy.

The total duration of the study per site is approximately 21 months, which includes a 6 months enrollment period, a prospective observation period of at least 12 months, and a period of maximum 3 months prior to the last blood test. Patients will only attend hospital visits planned as part of their standard treatment and they will receive treatment as a part of standard care and according to the doctor's discretion. The number of patient visits depends on the number of Monofer® treatment courses needed during the study period. Each patient can receive one or more treatment courses during 12 months after informed consent. The last blood test will be taken after the last Monofer® treatment course which might occur 13-15 months after informed consent. Study termination will occur once the 12 months observational period has been completed for all patients and the last blood test has been collected from the last Monofer® treated patient in the study. Each treatment course can consist of one or more Monofer® administrations. For each administration of Monofer® either intravenous infusion or injection can be used. Pre- and post-treatment blood tests according to standard treatment and quality of life assessments for fatigue symptoms (FACIT-Fatigue and IBD-F Scales) are a part of the Monofer® treatment course. Laboratory assessments, i.e. anaemia work-up/treatment evaluation, shall be a part of local standard practice. The protocol does not accept any additional samples outside current local standard practice to be taken.

Clinical data management will be performed in accordance with applicable standards and data cleaning procedures. The collected data will systematically be entered into an electronic case report form (eClinicalOS, myEDC, license by BioStata Aps Denmark). The sources of information are the relevant treatment and laboratory results obtained from patient records as well as the quality of life questionnaires for fatigue symptoms. The data will be evaluated by the Pharmacosmos Medical Affairs teams and an external Data Management vendor located in a country within the European Union.

Enrollment: 359 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with iron deficiency anaemia as a consequence of CKD or IBD (on the basis of local definition or clinical judgement), treated on the doctor's discretion with Monofer® as standard treatment according to current practice

Exclusion criteria

• Patients diagnosed with both CKD and IBD

Trial design

359 participants in 2 patient groups

CKD, iron deficiency anaemia

Description:

10% Iron Isomaltoside 1000 administered intravenously to Chronic Kidney Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.

Treatment:

Drug: 10% Iron Isomaltoside 1000

IBD, iron deficiency anaemia

Description:

10% Iron Isomaltoside 1000 administered intravenously to Inflammatory Bowel Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.

Treatment:

Drug: 10% Iron Isomaltoside 1000